BCL2 and cancer: Furthermore, either suppression of Mcl-1 or induction of NOXA sensitizes cells to ABT-737 in a variety of tumor models, suggesting that a treatment regime combining ABT-737 with a Mcl-1-specific inhibitor may be necessary to overcome the resistance against ABT-737 [24], [29], [30], [34], [35], as it is necessary to neutralize both arms of the anti-apoptotic Bcl-2 family (Bcl-2/Bcl-xL and Mcl-1) for apoptosis to occur in many cancer cell types.